Asia-Pacific API Intermediates Market Size (2023 – 2030)

The Asia-Pacific API Intermediates Market was valued at USD 7.48 Billion and is projected to reach a market size of USD 12.01 Billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 7%.

In recent years, the API intermediates market has grown significantly in the Asia-Pacific region. Chemical substances that are employed as raw materials or as precursors in the synthesis of active pharmaceutical ingredients (APIs) are known as API intermediates or active pharmaceutical ingredient intermediates. The market for API intermediates has expanded in the Asia-Pacific area as a result of the increasing demand for APIs, which has been fuelled by factors such as the increased prevalence of chronic diseases, population expansion, and bettering healthcare infrastructure. The Asia-Pacific region's sizeable and diverse pharmaceutical manufacturing sector is one of the major drivers boosting the market for API intermediates. API production is heavily concentrated in nations like China and India, which are also key actors in the global pharmaceutical business. These nations have well-established industrial infrastructure, a competent labor force, and supportive political environments that encourage the expansion of the pharmaceutical industry. They have consequently grown to be important suppliers of API intermediates to both home and foreign markets.

Due to factors like the region's thriving pharmaceutical manufacturing industry, cost advantages, changing disease trends, and government initiatives supporting domestic production, the market for Asia-Pacific API intermediates is rapidly growing. The region has the potential to serve as a significant hub for the production of API intermediates, notwithstanding challenges with quality control and regulatory compliance. As the need for APIs grows internationally, the Asia-Pacific region is well-positioned to capitalize on this potential and play a significant role in the pharmaceutical industry. 

Asia-Pacific API Intermediates Market Drivers:

The growing Pharmaceutical Industry in the Asia-Pacific Region is fuelling market growth.

The pharmaceutical sector in the Asia-Pacific region has expanded significantly, which is a key factor in the market for API intermediates. A vast population base, rising healthcare spending, and improved healthcare infrastructure have helped nations like China and India establish themselves as major players in the global pharmaceutical market. The region's pharmaceutical sector has expanded as a result of the increased frequency of chronic diseases and the desire for cutting-edge treatments. As necessary constituents in the manufacturing of active pharmaceutical ingredients, API intermediates are in high demand. The Asia-Pacific area has a well-established pharmaceutical manufacturing sector, which creates a favorable climate for API intermediates and draws both domestic and foreign businesses to the region.

Cost Advantage and a Favorable Business Environment is contributing toward market expansion.

The manufacture of API intermediates can be done more affordably and in an advantageous business climate in the Asia-Pacific region, which is what is fuelling the market's expansion. The region's nations, including China and India, profit from cheaper labor costs, a plentiful supply of raw materials, and a well-established infrastructure for the production of chemicals. These elements support the region's ability to produce API intermediates at competitive prices, luring pharmaceutical corporations to set up production units there. Governments in the Asia-Pacific area have also put laws and efforts in place to encourage indigenous pharmaceutical production and lessen reliance on imports. For instance, the "Make in India" initiative in India supports and promotes pharmaceutical businesses to produce APIs and API intermediates locally by offering financial incentives. Such programs foster a positive business climate and encourage investments in the API.

Asia-Pacific API Intermediates Market Challenges:

The availability of fake and inferior API intermediates on the market is one of the biggest issues the Asia-Pacific API intermediates industry has to deal with. False API intermediates may not adhere to the necessary quality requirements or contain the appropriate active components, which can pose serious concerns to patient safety and health consequences. The presence of fake and inferior API intermediates damages the standing of pharmaceutical firms and may result in regulatory problems. To overcome this difficulty, the Asia-Pacific area needs strong regulatory frameworks, stringent quality control procedures, and efficient enforcement methods to guarantee the reliability and caliber of API intermediates.

Asia-Pacific API Intermediates Market Opportunities:

The rising need for tailored medications is a significant business potential in the Asia-Pacific API intermediates industry. Personalizing medical care for each patient based on their unique genetic profile, lifestyle, and other characteristics is known as personalized medicine. To provide specialized treatments, this strategy necessitates a wide variety of API intermediates. With its sizable and diversified population, the Asia-Pacific region offers a major opportunity for the creation of API intermediates that facilitate personalized treatment. Companies that can provide this demand may be able to achieve a market competitive advantage. 

COVID-19 Impact on Asia-Pacific API Intermediates Market:

A greater emphasis is being placed on research and development in the healthcare industry, including the creation of vaccines, medicines, and diagnostics, as a result of the COVID-19 pandemic. The Asia-Pacific API intermediates market now offers more potential as a result of this increased R&D effort. The need for API intermediates has increased as more antiviral medications and vaccine parts need to be produced. The region's pharmaceutical manufacturers and businesses have been able to take advantage of the rising demand, which could result in revenue growth and market expansion. The global supply chains have been severely disrupted by the COVID-19 pandemic, which affects the Asia-Pacific API intermediates industry. The transit and accessibility of raw materials and completed goods have been hampered by trade restrictions, border closures, and lockdown measures. The production and delivery delays brought on by these interruptions have affected the overall supply of API intermediates. Businesses operating in the Asia-Pacific region struggle because of cost hikes and market turbulence brought on by supply chain volatility and unpredictability.

Asia-Pacific API Intermediates Market Recent Developments:

• In January 2021, Along with Vertellus CEO John Van Hulle and other members of the management team, Pritzker Private Capital purchased the maker of specialty chemicals Vertellus. Healthcare, personal care, food & agriculture, coatings, and transportation are just a few of the industries in which Vertellus, with its headquarters in Indianapolis, supplies specialty chemicals. Vertellus has been in business for more than 160 years and runs 10 factories all around the world, producing more than 700 items.

ASIA-PACIFIC API INTERMEDIATES  MARKET REPORT COVERAGE:

Asia-Pacific API Intermediates Market Segmentation:

Asia-Pacific API Intermediates Market Segmentation: By Type

• Pharmaceutical Intermediates/Bulk Drug Intermediates
• Veterinary Drug Intermediates

Two categories of segments can be produced in the Asia-Pacific API intermediates market: pharmaceutical intermediates/bulk drug intermediates and veterinary drug intermediates. The bulk drug intermediates and pharmaceutical intermediates markets in the area each hold a sizable market share. This is because countries like China and India, which are important suppliers of API intermediates, are developing the pharmaceutical industry. The market for pharmaceutical intermediates is influenced by factors like the prevalence of chronic diseases, the arising healthcare expenses, and the need for novel treatments. The market for veterinary medication intermediates is consistently growing in the Asia-Pacific region as a result of the rising demand for animal healthcare products. The market share of both pharmaceutical and veterinary drug intermediates is anticipated to increase as the region experiences a change in illness patterns and a propelling emphasis on personalized therapy.

Asia-Pacific API Intermediates Market Segmentation: By Product

• Nitriles
• Bromo Compound
• Chiral PCBHP
• Hemisulphate
• Others

Nitriles, bromo compounds, chiral PCBHP, hemisulfate, and other products can be found in the product segments of the Asia-Pacific API intermediates market. Nitriles have a substantial market share in the area among these segments. Nitriles are frequently employed in the creation of pharmaceutical intermediates and have a wide range of therapeutic uses, including cancer, cardiology, and nervous system medications. Due to their use in the synthesis of APIs, bromo compounds are also experiencing a significant rise in this market. Chiral PCBHP has become well-known in the pharmaceutical sector due to its chirality and selective reactions. Due to its use in the creation of antiviral medications, the hemisulfate market is anticipated to expand gradually. Various chemical compounds employed in the pharmaceutical production process are among the additional API intermediates that contribute. These market segments are anticipated to propel market expansion and nab a sizeable market share as the demand for varied API intermediates in the Asia-Pacific region keeps rising. 

Asia-Pacific API Intermediates Market Segmentation: By Therapeutic Type

• Cardiovascular Disease
• Metabolic Disease
• Respiratory Disease
• Oncology
• Others 

The therapeutic categories of cardiovascular disease, metabolic disease, respiratory disease, cancer, and others can be used to segment the Asia-Pacific API intermediates market. Cardiovascular disease has a sizable market share in the area among these segments. The demand for API intermediates used in the manufacturing of cardiovascular medications has increased due to the rising prevalence of cardiovascular disorders such as hypertension and coronary artery disease. The rising prevalence of diabetes and obesity is fueling the continuous rise of the metabolic illness market. The demand for API intermediates for respiratory drugs is influenced by respiratory disease, including ailments like asthma and chronic obstructive pulmonary disease (COPD). The development of targeted therapeutics and the rising incidence of cancer are both predicted to contribute to the oncology segment's strong growth. The API intermediates market also includes other therapeutic areas like infectious diseases and disorders of the central nervous system. These markets have chances for market expansion and market share growth in the API intermediates market as the Asia-Pacific region continues to encounter healthcare problems and observe a developing disease landscape.

Asia-Pacific API Intermediates Market Segmentation: By Country

• China
• Japan
• India
• South Korea
• Rest of the Asia-Pacific

Countries in the Asia-Pacific region's market for API intermediates include China, Japan, India, South Korea, and the rest of the region. China has a substantial market share in the region thanks to its robust pharmaceutical industry, established manufacturing capabilities, and helpful government policies. Japan contributes significantly to the market due to its advanced healthcare system and emphasis on research and development. India is a significant producer of API intermediates, taking advantage of its affordable rates, pool of qualified workers, and government-sponsored initiatives to boost domestic manufacturing. South Korea is seeing steady expansion in the market for API intermediates as a result of its technological advancements and pharmaceutical sector expenditures. The developing economies in the Asia-Pacific region have room for expansion. The need for API intermediates is projected to rise as these countries, especially those in Southeast Asia, put more emphasis on the development of their healthcare systems. The entire Asia-Pacific API intermediates market is dominated by China, Japan, and India, with additional countries contributing to the region's growth and market share. 

Asia-Pacific API Intermediates Market Key Players:

1. Sanofi
2. Aarti Industries Limited
3. Aurobindo Pharma
4. Divi's Laboratories Limited.
5. HIKAL Ltd.
6. Sandoz International GmbH
7. BASF SE
8. Cambrex Corporation
9. AlzChem Group AG
10. Vasudha Pharma
11. Anyang General Chemical Co., Ltd.